Lipid management in chronic kidney disease, hemodialysis, and transplantation.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Endocrinology and metabolism clinics of North America (Print)

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ecl.2008.11.004PMID 19217521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Air Force/Texas Coronary Atherosclerosis Prevention Study

  2008cited by this paper
• Mechanism of action of niacin.

  2008cited by this paper
• The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.

  2007cited by this paper
• Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study

  2007cited by this paper
• Lipoprotein metabolism and lipid management in chronic kidney disease.

  2007cited by this paper
• Management of dyslipidemias in patients with diabetes and chronic kidney disease.

  2006cited by this paper
• Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

  2005cited by this paper
• High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.

  2005cited by this paper
• Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

  2005cited by this paper
• Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.

  2005cited by this paper
• Dyslipidemias in patients who have chronic kidney disease.

  2005cited by this paper
• Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.

  2005cited by this paper
• Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

  2005cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.

  2004cited by this paper
• Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

  2004cited by this paper
• Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

  2004cited by this paper
• Managing dyslipidemia in chronic kidney disease

  2004cited by this paper
• Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post‐Hoc Subgroup Analyses of the ALERT Study

  2004cited by this paper
• Treatment of hyperlipidemia in cardiac transplant recipients.

  2004cited by this paper
• Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

  2004cited by this paper
• Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

  2003cited by this paper
• K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.

  2003cited by this paper
• Study of Heart and Renal Protection (SHARP).

  2003cited by this paper
• A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

  2003cited by this paper
• Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency

  2003cited by this paper
• Dialysis modalities and dyslipidemia.

  2003cited by this paper
• Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.

  2002cited by this paper
• A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients.

  2002cited by this paper
• Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

  2002cited by this paper
• HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

  2002cited by this paper
• Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study.

  2001cited by this paper
• Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.

  2000cited by this paper
• Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.

  2000cited by this paper
• Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

  2000cited by this paper
• Vitamin E supplementation and cardiovascular events in high-risk patients.

  2000cited by this paper
• Effect of Vitamins on the Lipid Profile of Patients on Regular Hemodialysis

  2000cited by this paper
• Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.

  2000cited by this paper
• Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.

  1999cited by this paper
• The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up.

  1999cited by this paper
• Effects of Gemfibrozil on Lipid and Hemostatic Factors in Capd Patients

  1999cited by this paper
• Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.

  1999cited by this paper
• Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up.

  1999cited by this paper
• Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism.

  1999cited by this paper
• Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

  1999cited by this paper
• Modification of Lipoproteins in Uremia: Oxidation, Glycation and Carbamoylation

  1999cited by this paper
• Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Safe Use of Gemfibrozil inUremic Patients on Continuous Ambulatory Peritoneal Di alysis

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Hyperlipidemia in patients with chronic renal disease.

  1998cited by this paper
• The emergence of triglycerides as a significant independent risk factor in coronary artery disease.

  1998cited by this paper
• Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation.

  1997cited by this paper
• Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.

  1997cited by this paper
• Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase.

  1997cited by this paper
• Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

  1997cited by this paper
• Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects.

  1997cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

  1996cited by this paper
• West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

  1996cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Has parathyroid hormone any influence on lipid metabolism in chronic renal failure?

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?

  1994cited by this paper
• Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation.

  1994cited by this paper
• The effects of fibrates on lipoprotein and hemostatic coronary risk factors.

  1994cited by this paper
• Severe defect in clearing postprandial chylomicron remnants in dialysis patients.

  1992cited by this paper
• Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients

  1992cited by this paper
• Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages.

  1991cited by this paper
• Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.

  1990cited by this paper
• Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.

  1990cited by this paper
• Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

  1986cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.

  1984cited by this paper
• Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias.

  1983cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction

  2025cites this paper
• Dyslipidemia in Patients with Kidney Disease.

  2021cites this paper
• Dyslipidemia: Pattern in Chronic Kidney Disease Patients in a Teaching Hospital in Nigeria

  2018cites this paper
• Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

  2017cites this paper
• Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)

  2014cites this paper
• Non-statin therapies for CKD with dyslipidemia

  2014cites this paper
• Postprandial hypertriglyceridemia and androgen dysfunction relationship in men with end stage renal disease

  2014cites this paper
• A Study of Lipid Profile in Chronic Kidney Disease Patients on Conservative Management, Haemodialysis and After Renal Transplantation

  2012cites this paper
• Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and high-sensitivity C-reactive protein in end-stage renal disease.

  2011cites this paper
• Glycemic control and cardiorenal outcomes in patients with advanced chronic kidney disease: relative or absolute risks?: comment on "Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease".

  2011cites this paper
• Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease.

  2011cites this paper
• Dyslipidemia in renal disease: causes, consequences and treatment.

  2010influential citation
• HDL metabolism and activity in chronic kidney disease

  2010cites this paper
• Lipid metabolism and causal pathways for cardiovascular disease in chronic kidney disease

  2009cites this paper
• Lipid metabolism and causal pathways for cardiovascular disease in chronic kidney disease.

  2009cites this paper
• Low levels of high‐density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients

  2009cites this paper